Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00316888 Phase II Cetuximab + Cisplatin + Fluorouracil + Radiotherapy Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer Completed USA 0
NCT03212469 Phase Ib/II Durvalumab + Tremelimumab A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) Active, not recruiting FRA 0
NCT03357757 Phase II Avelumab + Valproic acid Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) Active, not recruiting CAN 0
NCT03386500 Phase I BMX-001 Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer Recruiting USA 0
NCT03519295 Phase II Cisplatin + Docetaxel + Fluorouracil Atezolizumab + Cisplatin + Docetaxel + Fluorouracil A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma (SCARCE) Active, not recruiting FRA 0
NCT03946358 Phase II Atezolizumab + UCPVax Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) (VolATIL) Active, not recruiting FRA 0
NCT04046133 Phase I Pembrolizumab Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus (CORINTH) Unknown status GBR 1
NCT04230759 Phase II Durvalumab + Fluorouracil + Mitomycin C Fluorouracil + Mitomycin C Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group (RADIANCE) Active, not recruiting DEU | AUT 1
NCT04444921 Phase III Carboplatin + Paclitaxel Carboplatin + Nivolumab + Paclitaxel Testing the Addition of Nivolumab to Chemotherapy for Patients With Metastatic Anal Cancer Recruiting USA 0
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Active, not recruiting AUS 2
NCT04472429 Phase III Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Retifanlimab Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 5
NCT04536922 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab Single Patient Protocol: A Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizu... Withdrawn USA 0
NCT04929028 Phase II Capecitabine + Mitomycin C Nivolumab Fluorouracil + Mitomycin C Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Recruiting USA 0
NCT05544929 Phase I KFA115 KFA115 + Pembrolizumab A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Recruiting USA | ITA | ESP | DEU | CAN 4